Emergency Use Devices: Why Speed Doesn’t Exempt You from Evidence

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

Emergency use authorizations create regulatory space for faster market access. But this space is not an exemption from clinical evaluation requirements under MDR Article 61. It’s a temporary pathway with specific conditions and obligations that most manufacturers misunderstand until they face their first Notified Body review or post-market surveillance audit.

The core problem is conceptual. Teams interpret emergency as a signal to lower evidentiary standards. What it actually signals is the need for accelerated but still rigorous evidence collection, structured clinical evaluation, and explicit post-market commitments.

Let me walk through what this actually means in practice.

The Regulatory Framework for Emergency Use

MDR Article 59 allows derogations in duly justified cases of public health emergency. But these derogations apply to conformity assessment procedures, not to the fundamental requirement that devices must demonstrate clinical safety and performance.

This creates a specific tension: you can access the market faster, but you cannot skip the clinical evaluation logic defined in MDR Annex XIV and MDCG 2020-5. You must still generate a clinical evaluation report that demonstrates benefit-risk is acceptable based on available evidence.

The difference is in what constitutes “available evidence” during an emergency, and what commitments you make to generate additional evidence post-authorization.

What Changes Under Emergency Pathways

In normal circumstances, your clinical evaluation must be complete before you submit for conformity assessment. Under emergency use, you can structure your evidence package differently, but you must be explicit about what you have, what you lack, and what you will generate.

Here’s what actually changes:

Timeline compression: You may rely on preliminary data from ongoing studies rather than waiting for final results. But you must document the study design, interim findings, and timelines for completion.

Evidence gaps: You can acknowledge specific evidence gaps if you justify why they are acceptable in the emergency context and commit to addressing them. This is not a waiver. It’s a structured deferral with obligations.

Equivalence pathways: You may rely more heavily on equivalence to existing devices if direct clinical data is limited. But the equivalence demonstration must still meet MDR requirements: technical, biological, and clinical equivalence must be established, not assumed.

What does not change is the need for a systematic literature review, appraisal of available data, and benefit-risk analysis. You cannot skip these steps because you are operating under emergency conditions.

Structuring the Clinical Evaluation Report

Your CER under emergency use must explicitly address the temporary nature of the authorization and the evidence gaps you are managing.

This means you need a section that identifies what evidence is currently available, what evidence is missing, and what specific studies or data collection activities will address the gaps. This is not optional language. It is the foundation of your emergency justification.

In every emergency use CER I’ve reviewed, the quality of this section determines whether the submission moves forward or stalls. If you list gaps without clear plans, you signal uncertainty. If you list plans without timelines and endpoints, you signal lack of rigor.

The structure should be clear: for each evidence gap, state what is missing, why it is acceptable to proceed without it in the emergency context, and what post-market activity will generate it. Include specific study protocols, data collection schedules, and analysis plans.

This is not about promising everything. It’s about demonstrating you understand the gaps and have structured your post-market obligations to address them systematically.

The Literature Review Challenge

One of the most common mistakes is assuming you can perform a limited literature search during emergency use. You cannot.

MDR Annex XIV Part A requires a comprehensive review of the state of the art and relevant scientific literature. This requirement does not disappear because you are operating under an emergency pathway. What changes is how you manage literature that is still emerging.

In an emergency, relevant literature may be pre-print, preliminary, or rapidly evolving. Your literature review must acknowledge this and appraise the quality of available publications accordingly. You may include pre-prints if you justify their inclusion and note the limitations. You may reference ongoing studies if you document their design and expected timelines.

What you cannot do is conduct a narrow search, exclude relevant databases, or skip critical appraisal because time is limited. The search must be comprehensive. The appraisal must be systematic. The reporting must be transparent.

Here’s the logic reviewers follow: if you have time to prepare a submission, you have time to conduct a proper literature search. The emergency affects your market access timeline, not your ability to search PubMed, Embase, and relevant registries.

Post-Market Commitments and PMCF

The second half of your emergency use strategy is the post-market clinical follow-up plan. This is where most submissions fail to meet expectations.

Your PMCF plan under emergency use must be more detailed, more specific, and more binding than a standard PMCF plan. It is the mechanism through which you fulfill the commitments you made when you acknowledged evidence gaps.

This means your PMCF plan must include:

Specific studies: Not generic surveillance. Structured studies with protocols, endpoints, sample sizes, and analysis plans. Each study should correspond to an evidence gap you identified in the CER.

Clear timelines: When will data collection begin? When will interim analyses occur? When will final reports be available? These timelines must be realistic and must align with the urgency that justified the emergency pathway.

Defined triggers: What findings would require you to update the CER, modify the device, or restrict the indications? These triggers must be explicit, measurable, and tied to benefit-risk reassessment.

In practice, this means your PMCF plan cannot be a standard template with generic language. It must be a structured commitment document that demonstrates you understand what evidence you are still generating and how you will act on it.

Benefit-Risk Under Uncertainty

The benefit-risk analysis in an emergency use CER must explicitly acknowledge uncertainty and justify why the balance is still acceptable.

This is different from a standard benefit-risk analysis where you present evidence and conclude the balance is favorable. In an emergency context, you present evidence, acknowledge what is missing, and justify why the available evidence combined with post-market commitments supports a positive balance in the specific emergency situation.

The justification must reference the emergency context: the severity of the health threat, the lack of therapeutic alternatives, the preliminary evidence of benefit, and the measures in place to monitor and manage risks as more data becomes available.

This is not a lower standard. It is a different framing. You are not saying the evidence is complete. You are saying the available evidence, in the context of the emergency and with structured post-market follow-up, supports proceeding.

Reviewers assess this by checking whether your uncertainty acknowledgment is honest, whether your post-market commitments are credible, and whether your benefit-risk reasoning accounts for the gaps you have identified.

When Emergency Authorization Ends

One aspect manufacturers often miss: emergency use authorization is temporary. At some point, you must transition to full MDR compliance or remove the device from the market.

This transition requires a complete CER that no longer relies on emergency justifications. All the evidence gaps you acknowledged must be addressed. All the post-market commitments must be fulfilled or in progress with interim data available.

If you structured your emergency submission correctly, this transition is straightforward: you update the CER with the post-market data you committed to generating, you remove the emergency justification language, and you demonstrate that benefit-risk is now supported by complete evidence.

If you did not structure the submission correctly, the transition becomes a new conformity assessment with all the evidence requirements you thought you had bypassed. This is where teams discover that speed without rigor creates future regulatory debt.

What This Means for Your Next Submission

If you are preparing a clinical evaluation for emergency use, your approach must balance speed with structure.

Start with a complete literature search. Do not assume you can defer this. The search can be conducted quickly if you have the right resources and focus. Appraise what is available honestly, including preliminary or emerging data with appropriate caveats.

Document every evidence gap explicitly in the CER. For each gap, provide a clear justification for why proceeding is acceptable in the emergency context and a specific plan for addressing the gap post-market.

Build a PMCF plan that is more detailed than you think is necessary. Include protocols, timelines, endpoints, and triggers. This plan is not administrative paperwork. It is the foundation of your regulatory commitment.

Structure your benefit-risk analysis to acknowledge uncertainty and justify the balance in the context of the emergency. Do not pretend the evidence is complete. Demonstrate that the available evidence supports proceeding with conditions.

Emergency pathways exist because public health needs sometimes require faster access to medical devices. But faster access does not mean less rigor. It means compressed timelines with explicit commitments to generate evidence systematically and transparently.

The manufacturers who succeed under emergency pathways are the ones who understand this distinction from the beginning.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.